Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alligator Bioscience ABFRA:7AL0 Equity-to-Asset is 0.05 as of Jun. 2026, which is 94% below its 10-year median of 0.79. The stock has 6 warning signs investors should review. Among 1,412 Biotechnology companies, Alligator Bioscience AB ranks worse than 86.05% on this metric.
Alligator Bioscience AB (FRA:7AL0) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Alligator Bioscience AB Equity-to-Asset Related Terms
Alligator Bioscience AB Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7AL0 vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Alligator Bioscience AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alligator Bioscience AB Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Alligator Bioscience AB's Equity-to-Asset falls into.
Alligator Bioscience AB Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Alligator Bioscience AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alligator Bioscience AB (FRA:7AL0) has a Equity-to-Asset of 0.05 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Alligator Bioscience AB and its competitors. This is 94% below median its historical median of 0.79. According to the industry distribution chart, Alligator Bioscience AB ranks #1215 out of 1412 companies in the Biotechnology industry, placing it in the top 86%.
Is Alligator Bioscience AB's Equity-to-Asset too high?
Alligator Bioscience AB's current Equity-to-Asset of 0.05 is 94% below median its 10-year median of 0.79. The Biotechnology industry median Equity-to-Asset is 0.69. Alligator Bioscience AB's value of 0.05 is 92.8% below this industry median. Based on the distribution chart, Alligator Bioscience AB ranks #1215 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Alligator Bioscience AB's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alligator Bioscience AB ranks #1215 out of 1412 companies for Equity-to-Asset. This places Alligator Bioscience AB in the lower half of its industry. The industry median Equity-to-Asset is 0.69. Alligator Bioscience AB's value of 0.05 is 92.8% below this benchmark. While the company's 10-year median is 0.79 vs. the industry median of 0.69, Alligator Bioscience AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alligator Bioscience AB's current Equity-to-Asset of 0.05 is 92.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Alligator Bioscience AB and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alligator Bioscience AB's current Equity-to-Asset is 0.05, which is 94% below median its own 10-year median of 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alligator Bioscience AB stock overvalued right now?
Alligator Bioscience AB (FRA:7AL0) has a current Equity-to-Asset of 0.05. The current Equity-to-Asset is 0.05, which is 94% below median its 10-year median of 0.79 and 92.8% below the Biotechnology industry median of 0.69. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Alligator Bioscience AB (FRA:7AL0), the current Equity-to-Asset is 0.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7AL0 has been successfully added to your 
